Table 3. Correlation of clinicopathological parameters with pCR in the trastuzumab-treated and lapatinib-treated patient group (multivariate analysis).
|
Trastuzumab
|
Lapatinib
|
|||
|---|---|---|---|---|
| Baseline characteristics | Odds ratio | P-value | Odds ratio | P-value |
| T3/4 vs T1/2 | 2.1 | 0.15 | 0.71 | 0.59 |
| G3 vs G1/2 | 1.9 | 0.18 | 1.22 | 0.73 |
| cN0 vs cN1 | 2.2 | 0.12 | 3.78 | 0.033 |
| HR positive vs HR negative | 0.5 | 0.17 | 0.21 | 0.013 |
| Pre-chemotherapy sHER2 levels | 1.5 | 0.49 | 10.8 | 0.01 |
| sHER2 decrease >20% vs sHER2 decrease ⩽ 20% | 2.76 | P=0.07 | 11.7 | 0.031 |
Abbreviations: HR=hormone receptor; pCR=pathological complete remission; sHER2=serum HER2.